Esomeprazole Magnesium

DRUG7 trials

Sponsors

Astrazeneca AB, Medstar Health Research Institute, National Cancer Institute (NCI), AstraZeneca, City of Hope Medical Center

Conditions

Barrett EsophagusBarrett's EsophagusDyspepsiaEndoscopically-Proven GERDErosive EsophagitisEsophageal CancerGastroesophageal Reflux DiseaseHealthy

Phase 1

Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)

CompletedNCT00687245

AstraZenecaEndoscopically-Proven GERD, Reflux

Start: 2006-08-31End: 2008-05-31Updated: 2008-06-11

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

CompletedNCT01135472

City of Hope Medical CenterHealthy

Start: 2010-03-31End: 2012-04-30Updated: 2012-12-18

Phase 2

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

CompletedNCT00474903

National Cancer Institute (NCI)Barrett Esophagus, Esophageal Cancer

Start: 2007-04-30End: 2011-06-30Updated: 2014-07-02

Phase 3

A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age

Active, not recruitingCTIS2023-505454-18-00

Astrazeneca ABErosive Esophagitis

Start: 2021-11-24Target: 54Updated: 2025-09-11

Phase 4

Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

WithdrawnNCT00443963

Medstar Health Research InstituteDyspepsia

Start: 2006-12-31End: 2006-12-31Updated: 2020-08-24

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)

CompletedNCT00637845

AstraZenecaGastroesophageal Reflux Disease, Heartburn

Start: 2002-06-30End: 2003-02-28Updated: 2011-01-21

Barrett's Esophagus - 315 - 3 Way Cross-Over

CompletedNCT00637559

AstraZenecaBarrett's Esophagus

Start: 2002-03-31End: 2003-04-30Target: 50Updated: 2011-01-25

Related Papers

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

2012-07-1142 citations